Krithika Muthuraman
Overview
Explore the profile of Krithika Muthuraman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
377
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aschner C, Muthuraman K, Kucharska I, Cui H, Prieto K, Nair M, et al.
Sci Transl Med
. 2023 May;
15(697):eadf4549.
PMID: 37224226
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has been responsible for a global pandemic. Monoclonal antibodies (mAbs) have been used as antiviral...
2.
Kassardjian A, Sun E, Sookhoo J, Muthuraman K, Boligan K, Kucharska I, et al.
Cell Rep
. 2023 Apr;
42(4):112391.
PMID: 37053069
Subunit vaccines typically require co-administration with an adjuvant to elicit protective immunity, adding development hurdles that can impede rapid pandemic responses. To circumvent the need for adjuvant in a severe...
3.
Icho S, Rujas E, Muthuraman K, Tam J, Liang H, Landreth S, et al.
Antimicrob Agents Chemother
. 2022 Jun;
66(7):e0043922.
PMID: 35703551
An essential step in the infection life cycle of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the proteolytic activation of the viral spike (S) protein, which enables membrane...
4.
Rujas E, Cui H, Burnie J, Aschner C, Zhao T, Insausti S, et al.
Proc Natl Acad Sci U S A
. 2022 Jan;
119(4).
PMID: 35064083
Deep mining of B cell repertoires of HIV-1-infected individuals has resulted in the isolation of dozens of HIV-1 broadly neutralizing antibodies (bNAbs). Yet, it remains uncertain whether any such bNAbs...
5.
Hsieh C, Werner A, Leist S, Stevens L, Falconer E, Goldsmith J, et al.
Cell Rep
. 2021 Oct;
37(5):109929.
PMID: 34710354
Current coronavirus (CoV) vaccines primarily target immunodominant epitopes in the S1 subunit, which are poorly conserved and susceptible to escape mutations, thus threatening vaccine efficacy. Here, we use structure-guided protein...
6.
Rujas E, Kucharska I, Tan Y, Benlekbir S, Cui H, Zhao T, et al.
Nat Commun
. 2021 Jun;
12(1):3661.
PMID: 34135340
SARS-CoV-2, the virus responsible for COVID-19, has caused a global pandemic. Antibodies can be powerful biotherapeutics to fight viral infections. Here, we use the human apoferritin protomer as a modular...
7.
Jones B, Brown-Augsburger P, Corbett K, Westendorf K, Davies J, Cujec T, et al.
Sci Transl Med
. 2021 Apr;
13(593).
PMID: 33820835
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies are a key class of therapeutics that may...
8.
Jones B, Brown-Augsburger P, Corbett K, Westendorf K, Davies J, Cujec T, et al.
bioRxiv
. 2020 Oct;
PMID: 33024963
One Sentence Summary: LY-CoV555, an anti-spike antibody derived from a convalescent COVID-19 patient, potently neutralizes SARS-CoV-2 and protects the upper and lower airways of non-human primates against SARS-CoV-2 infection.